• Innovent Biologics posted IFRS profit of RMB 1.25 billion, up 50.2% year over year, on revenue of RMB 8.62 billion, up 44.8%.
• Product revenue climbed 56.7% to RMB 8.2 billion, with management citing contributions from general biomedicine and newly NRDL-listed oncology products.
• IFRS gross profit rose 43% to RMB 7.32 billion; gross margin narrowed 1 percentage point to 85%.
• Non-IFRS profit increased 40.5% to RMB 1.7 billion; non-IFRS EBITDA advanced 47.1% to RMB 2.08 billion.
• Portfolio expanded to 20 marketed products, 13 on the NRDL; arcotatug tavatecan (IBI343/TAK-921) received NMPA priority review in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12298144), on August 25, 2026, and is solely responsible for the information contained therein.